Patents Assigned to Starpharma Pty Ltd.
-
Patent number: 11970583Abstract: Provided herein are dendrimers comprising: a core unit, five generations of building units which are lysine residues or analogues thereof, first terminal groups comprising a cabazitazel residue covalently attached to a diglycolyl linker group, and second terminal groups comprising a PEG group. Also provided herein are pharmaceutical compositions comprising the dendrimers, and methods and uses of the dendrimers in therapy of disorders such as cancers. Processes for making the dendrimers and intermediates are also provided.Type: GrantFiled: August 25, 2021Date of Patent: April 30, 2024Assignee: Starpharma Pty Ltd.Inventors: David James Owen, Brian Devlin Kelly
-
Patent number: 11118016Abstract: Provided herein are dendrimers comprising: a core unit, five generations of building units which are lysine residues or analogues thereof, first terminal groups comprising a cabazitazel residue covalently attached to a diglycolyl linker group, and second terminal groups comprising a PEG group. Also provided herein are pharmaceutical compositions comprising the dendrimers, and methods and uses of the dendrimers in therapy of disorders such as cancers. Processes for making the dendrimers and intermediates are also provided.Type: GrantFiled: August 26, 2020Date of Patent: September 14, 2021Assignee: Starpharma Pty Ltd.Inventors: David Owen, Brian Devlin Kelly
-
Patent number: 10730999Abstract: The present invention generally relates to macromolecules of dendrimer-drug conjugates. In particular, the invention relates to macromolecules comprising a pharmaceutically active agent, such as a protein or peptide, attached to a core of a dendrimer derived from branched building units, such as lysine or lysine analogues. The invention also relates to the synthesis of the dendrimers and macromolecules, and the use of such macromolecules, particularly in therapeutic applications, and pharmaceutical compositions comprising them.Type: GrantFiled: June 5, 2015Date of Patent: August 4, 2020Assignee: Starpharma Pty LtdInventors: David James Owen, Pauline Stanislawski, Michael Giannis, Oliver Bernhard
-
Patent number: 10265409Abstract: A macromolecule includes i) a dendrimer with a core and at least one generation of lysine residue building units, the outermost generation of building units having surface amino groups, ii) a first terminal group covalently attached to a first surface amino group of a building unit, which includes a residue of docetaxel (DTX), and iii) a second terminal group covalently attached to a second surface amino group of a building unit, which includes a pharmacokinetic modifying agent. The pharmacokinetic modifying agent can be a polyethylene glycol (PEG). The first terminal group can be covalently attached to the surface amino group of the dendrimer through a diacid linker. The diacid linker can include a 2,2?-thiodiacetic acid residue. The diacid linker can form an ester bond with a hydroxyl group of the DTX and an amide bond with the surface amino group. A pharmaceutically acceptable salt of the macromolecule can be prepared.Type: GrantFiled: August 28, 2017Date of Patent: April 23, 2019Assignee: STARPHARMA PTY LTDInventors: David Owen, Brian Devlin Kelly, Peter Karellas
-
Patent number: 9744246Abstract: The present invention relates to a macromolecule comprising a dendrimer having surface amino groups to which at least two different terminal groups are attached including a pharmaceutically active agent and a pharmacokinetic modifying agent, the pharmaceutically active agent comprising a hydroxyl group and being attached to the surface amino group of the dendrimer through a diacid linker. Pharmaceutical compositions comprising the macromolecules and methods of treatment using the macromolecules are also described.Type: GrantFiled: June 6, 2012Date of Patent: August 29, 2017Assignee: STARPHARMA PTY LTDInventors: David Owen, Brian Devlin Kelly, Peter Karellas
-
Patent number: 9585387Abstract: PEHAM dendrimers of the formula: Specific PEHAM dendrimers are used in a formulation with an active agent for agricultural purposes. In particular, the PEHAM dendrimers may be used for increasing the efficacy of the active agent in various ways, such as by improving solubility of the active agent in the formulation, by improving adhesion and penetration of the active agent to plant surfaces, or by improving the water-fastness of the active agent to the plant or seed. The PEHAM dendrimers may also increase the efficacy of the active agent by increasing soil penetration of the active agent to reach the plant roots or under soil parts, by reducing soil adhesion of the active agent to reach the plant roots or under soil parts, or by reducing enzymatic degradation of the active agent by the plant or seed or microorganisms in the soil.Type: GrantFiled: February 16, 2015Date of Patent: March 7, 2017Assignee: STARPHARMA PTY LTDInventors: Ryan T. Hayes, David James Owen, Abhay Singh Chauhan, Veera Reddy Pulgam, Harsh Vardhan
-
Patent number: 9127130Abstract: The present invention relates generally to branched macromolecules and their use as imaging or contrast agents. In particular, the invention relates to dendrimers, derived from lysine or lysine analogs, bearing a plurality of functional moieties and their application to imaging techniques in which a disease state may be imaged with a targeted contrast agent.Type: GrantFiled: August 10, 2007Date of Patent: September 8, 2015Assignees: STARPHARMA PTY LTD., BAKER IDI HEART AND DIABETES INSTITUTE HOLDINGS LTDInventors: Guy Yeoman Krippner, Zemin Wu, Karlheinz Peter, Christoph Hagemeyer, David Owen
-
Publication number: 20140171375Abstract: The present invention relates to a macromolecule comprising a dendrimer having surface amino groups to which at least two different terminal groups are attached including a pharmaceutically active agent and a pharmacokinetic modifying agent, the pharmaceutically active agent comprising a hydroxyl group and being attached to the surface amino group of the dendrimer through a diacid linker. Pharmaceutical compositions comprising the macromolecules and methods of treatment using the macromolecules are also described.Type: ApplicationFiled: June 6, 2012Publication date: June 19, 2014Applicant: STARPHARMA PTY LTDInventors: David Owen, Brian Devlin Kelly, Peter Karellas
-
Publication number: 20130116432Abstract: The present invention relates to a macromolecule having a controlled terminal group stoichiometry, the macromolecule including a surface layer, at least one subsurface layer and at least two terminal groups including: a first terminal group which is a residue of a pharmaceutically active agent, a derivative thereof or precursor therefor; and a second terminal group selected to modify the pharmacokinetics of the pharmaceutically active agent and/or macromolecule, wherein terminal group stoichiometry refers to the number and type of terminal groups.Type: ApplicationFiled: December 21, 2012Publication date: May 9, 2013Applicant: STARPHARMA PTY LTDInventor: Starpharma Pty Ltd
-
Patent number: 8420067Abstract: The present invention relates generally to branched macromolecules bearing functional moieties. In particular, the invention relates to dendrimers, derived from lysine or lysine analogues, bearing a plurality of functional moieties. The invention further relates to the use of such macromolecules, particularly in therapeutic applications, and compositions comprising them.Type: GrantFiled: August 10, 2007Date of Patent: April 16, 2013Assignee: Starpharma Pty LtdInventors: Guy Yeoman Krippner, Charlotte Claire Williams, Brian Devlin Kelly, Scott Andrew Henderson, Zemin Wu, Pasquale Razzino
-
Patent number: 8158575Abstract: Use of a polylysine, polyamidoamine or polypropylenimine dendrimer having naphthyl disulphonate terminal groups as a topically applied agent in prophylaxis or treatment of sexually transmitted diseases.Type: GrantFiled: July 6, 2009Date of Patent: April 17, 2012Assignee: Starpharma Pty., LtdInventors: Barry Ross Matthews, George Holan, Peter Karellas, Scott Andrew Henderson, David Francis O'Keefe
-
Publication number: 20110230348Abstract: Specific PEHAM dendrimers are used in a formulation with an active agent for agricultural purposes, particularly for increasing the efficacy of the active agent in various ways, such as by improving solubility of the active agent in the formulation, by improving adhesion and penetration of the active agent to plant surfaces, by improving the water-fastness of the active agent to the plant or seed, by increasing soil penetration of the active agent to reach the plant roots or under soil parts, or by reducing soil adhesion of the active agent to reach the plant roots or under soil parts, or reducing enzymatic degradation of the active agent by the plant or seed or microorganisms in the soil.Type: ApplicationFiled: May 4, 2011Publication date: September 22, 2011Applicants: Dendritic Nanotechnologies, Inc., Starpharma Pty LtdInventors: Ryan T. Hayes, David James Owen, Abhay Singh Chauhan, Veera Reddy Pulgam
-
Publication number: 20100324146Abstract: The present invention relates generally to the use of dendrimer compounds bearing anionic surface groups as inhibitors of hyaluronidase and their use in the treatment of diseases and conditions in which excessive, abnormal or unwanted levels of hyaluronidase are involved or implicated, or in the treatment of diseases or conditions in which the presence or administration of hyaluronic acid is therapeutically effective. The present invention also relates to pharmaceutical compositions and methods for the treatment of such diseases and conditions.Type: ApplicationFiled: February 20, 2009Publication date: December 23, 2010Applicant: Starpharma Pty LtdInventor: Jacinth Kincaid Fairley
-
Publication number: 20100292148Abstract: The present invention relates generally to branched macromolecules bearing functional moieties. In particular, the invention relates to dendrimers, derived from lysine or lysine analogues, bearing a plurality of functional moieties. The invention further relates to the use of such macromolecules, particularly in therapeutic applications, and compositions comprising them.Type: ApplicationFiled: August 10, 2007Publication date: November 18, 2010Applicant: STARPHARMA PTY LTD.Inventors: Guy Yeoman Krippner, Charlotte Claire Williams, Brian Devlin Kelly, Scott Andrew Henderson, Zemin Wu, Pasquale Razzino
-
Publication number: 20100278750Abstract: The present invention relates generally to branched macromolecules and their use as imaging or contrast agents. In particular, the invention relates to dendrimers, derived from lysine or lysine analogues, bearing a plurality of functional moieties and their application to imaging techniques in which a disease state may be imaged with a targeted contrast agent.Type: ApplicationFiled: August 10, 2007Publication date: November 4, 2010Applicants: STARPHARMA PTY LTD, BAKER MEDICAL RESEARCH INSTITUTEInventors: Guy Yeoman Krippner, Zemin Wu, Karlheinz Peter, Christoph Hagemeyer, David Owen
-
Publication number: 20090324535Abstract: The present invention relates to a macromolecule having a controlled terminal group stoichiometry, the macromolecule including a surface layer, at least one subsurface layer and at least two terminal groups including: a first terminal group which is a residue of a pharmaceutically active agent, a derivative thereof or precursor therefor; and a second terminal group selected to modify the pharmacokinetics of the pharmaceutically active agent and/or macromolecule, wherein terminal group stoichiometry refers to the number and type of terminal groups.Type: ApplicationFiled: May 15, 2006Publication date: December 31, 2009Applicant: Starpharma Pty LtdInventors: Benjamin James Boyd, Lisa Michelle Kaminskas, Christopher John Hamilton Porter, Peter Karellas, Guy Yeoman Krippner, Pasquale Razzino, Brian Devlin Kelly, Zemin Wu, Sue Pallich
-
Patent number: 7589056Abstract: Use of a polylysine, polyamidoamine or polypropylenimine dendrimer having naphthyl disulphonate terminal groups as a topically applied agent in prophylaxis or treatment of sexually transmitted diseases.Type: GrantFiled: March 28, 2002Date of Patent: September 15, 2009Assignee: Starpharma Pty. Ltd.Inventors: Barry Ross Matthews, George Holan, Peter Karellas, Scott Andrew Henderson, David Francis O'Keefe
-
Patent number: 7572459Abstract: To inhibit, prophylactically or therapeutically, a bacterial, yeast, fungal, or parasitic agent in a patient, an effective amount of a dendrimer is administered to the patient, which dendrimer has a plurality of terminal groups, at least one of which has an anionic- or cationic-moiety covalently bonded or linked thereto. The anionic-containing moiety is not a disaccharide or oligosaccharide moiety, and, where the anionic-containing moiety is a neuraminic- or sialic acid-containing moiety, it is modified in the 4-position by substitution with an amino, amido, cyano, azido or guanido group, or is unsaturated.Type: GrantFiled: August 26, 2002Date of Patent: August 11, 2009Assignee: Starpharma Pty Ltd.Inventors: Barry Ross Matthews, George Holan